India’s evolving role in global pharma and biotech took center stage at BioAsia 2025, highlighting innovation, AI-driven research, and clinical trials. Industry leaders stressed the need for regulatory reforms and competitive strategies to match China’s rapid rise. As AI transforms drug development and CRDMO opportunities grow, the key question remains—will India lead or lag? Read more: https://pharma.economictimes.indiatimes.com/news/pharmatech/innovation-ai-trials-and-india-at-the-cusp-of-a-global-pharma-and-biotech-reset/118596480